Literature DB >> 2824596

Detection and characterization of autoantibodies blocking the TSH-dependent cAMP production using FRTL-5 cells.

L Chiovato1, P Vitti, A Lombardi, G Lopez, F Santini, E Macchia, G F Fenzi, C Mammoli, S Battiato, A Pinchera.   

Abstract

Autoantibodies blocking the TSH-stimulated cAMP production (TBkAb) were measured in immunoglobulin G (IgG) preparations from 38 patients with primary autoimmune hypothyroidism, using FRTL-5 cells. TBkAb were detectable in 15/23 IgG preparations from patients with untreated idiopathic myxedema, and in 2/15 IgGs from patients under L-thyroxine treatment. None of the IgG from 22 normal subjects or from 10 patients with nonautoimmune hypothyroidism following total thyroidectomy caused any significant effect on the TSH-stimulated cAMP production. No correlation was found between TBkAb and the thyroid microsomal antibody. Antibodies inhibiting the 125I-TSH binding to TSH receptor were detectable in only 3/20 patients; IgGs from these 3 patients were also positive in the TBkAb assay. One IgG with potent TBkAb activity inhibited the TSH-stimulated adenylate cyclase in a competitive manner, while it had no effect on the forskolin-stimulated cAMP production. The inhibiting action of this IgG was almost completely lost after preabsorption with human thyroid membranes. In conclusion, we describe a new practical and sensitive method for the measurement of TBkAb; TBkAb are distinct from the microsomal antibody, and are probably directed to the TSH receptor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824596     DOI: 10.1007/BF03348154

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

1.  Radio-receptor assay of TSH: its use to detect thyroid-stimulating immunoglobulins.

Authors:  G Fenzi; E Macchia; L Bartalena; F Mazzanti; L Baschieri; L J DeGroot
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

2.  Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins.

Authors:  N Matsuura; Y Yamada; Y Nohara; J Konishi; K Kasagi; K Endo; H Kojima; K Wataya
Journal:  N Engl J Med       Date:  1980-09-25       Impact factor: 91.245

3.  Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' disease.

Authors:  U Bogner; H Schleusener; J R Wall
Journal:  J Clin Endocrinol Metab       Date:  1984-10       Impact factor: 5.958

4.  Blocking activity to action of thyroid stimulating hormone in serum from patients with primary hypothyroidism.

Authors:  N R Steel; D R Weightman; J J Taylor; P Kendall-Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-26

5.  Graves' IgG stimulation of continuously cultured rat thyroid cells: a sensitive and potentially useful clinical assay.

Authors:  P Vitti; W A Valente; F S Ambesi-Impiombato; G F Fenzi; A Pinchera; L D Kohn
Journal:  J Endocrinol Invest       Date:  1982 May-Jun       Impact factor: 4.256

6.  A new solid-phase immunoradiometric assay for anti-thyroglobulin autoantibody.

Authors:  S Mariotti; S Pisani; A Russova; A Pinchera
Journal:  J Endocrinol Invest       Date:  1982 Jul-Aug       Impact factor: 4.256

7.  Inhibition of thyrotropin-induced adenosine 3'5'-monophosphate increase by immunoglobulins from patients with primary myxedema.

Authors:  J Konishi; Y Iida; K Endo; T Misaki; Y Nohara; N Matsuura; T Mori; K Torizuka
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

8.  Characterization of the optimal stimulatory effects of graves' monoclonal and serum immunoglobulin G on adenosine 3',5'-monophosphate production in fRTL-5 thyroid cells: a potential clinical assay.

Authors:  P Vitti; C M Rotella; W A Valente; J Cohen; S M Aloj; P Laccetti; F S Ambesi-Impiombato; E F Grollman; A Pinchera; R Toccafondi; L D Kohn
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

Review 9.  Forskolin: a unique diterpene activator of cyclic AMP-generating systems.

Authors:  K B Seamon; J W Daly
Journal:  J Cyclic Nucleotide Res       Date:  1981

10.  Thyroid growth-blocking antibodies in primary myxoedema.

Authors:  H A Drexhage; G F Bottazzo; L Bitensky; J Chayen; D Doniach
Journal:  Nature       Date:  1981-02-12       Impact factor: 49.962

View more
  6 in total

1.  Binding of thyroglobulin (Tg) to the low-density lipoprotein receptor-associated protein (RAP) during the biosynthetic pathway prevents premature Tg interactions with sortilin.

Authors:  R Botta; S Lisi; G Rotondo Dottore; P Vitti; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-04-05       Impact factor: 4.256

2.  The expression of the microsomal/peroxidase autoantigen in human thyroid cells is thyrotrophin-dependent.

Authors:  L Chiovato; P Vitti; P Cucchi; C Mammoli; P Carajon; A Pinchera
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Detection of antibodies blocking thyrotropin effect using Chinese hamster ovary cells transfected with the cloned human TSH receptor.

Authors:  L Chiovato; P Vitti; G Bendinelli; F Santini; E Fiore; A Capaccioli; M Tonacchera; C Mammoli; M Ludgate; A Pinchera
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

4.  Intracellular retention of thyroglobulin in the absence of the low-density lipoprotein receptor-associated protein (RAP) is likely due to premature binding to megalin in the biosynthetic pathway.

Authors:  S Lisi; R Botta; G Rotondo Dottore; M Leo; F Latrofa; P Vitti; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-04-19       Impact factor: 4.256

5.  Reply to Drs. Kiaei and Molinaro Regarding the Publication "Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation".

Authors:  Stephanie Allelein; Tanja Diana; Matthias Schott; George J Kahaly
Journal:  Horm Metab Res       Date:  2020-02-13       Impact factor: 2.936

Review 6.  Thyrotropin Receptor Blocking Antibodies.

Authors:  Tanja Diana; Paul D Olivo; George J Kahaly
Journal:  Horm Metab Res       Date:  2018-10-04       Impact factor: 2.936

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.